In Lu’s study, CEUS shows promise in assessing non-Hodgkin’s lymphoma response to R-CHOP/CHOP therapy, as perfusion changes precede morphological alterations in indicating treatment efficacy and pretreatment PI values may help predict perfusion response and outcomes (10). This evidence concerns the gene DDIT3 and non-Hodgkin lymphoma.